Clinical characteristics, predictors of mortality, and outcome in patients with heart failure with mildly reduced ejection fraction secondary to Chagas cardiomyopathy.

• Tác giả: Reinaldo B Bestetti, Augusto Cardinalli-Neto, Maurício Nassau Machado, Marcelo A Nakazone, Ana Paula Otaviano
• Ngôn ngữ: eng
• Ký hiệu phân loại: 025.3492 Bibliographic analysis and control
• Thông tin xuất bản: Netherlands : International journal of cardiology , 2025
• Bộ sưu tập: NCBI
• ID: 552505

Tóm tắt

 Clinical characteristics, predictors of mortality, and outcome of patients with Chagas cardiomyopathy (ChCM) with heart failure with mildly reduced ejection fraction (HFmrEF) are unknown. 215 patients with a positive serology for ChCM and a left ventricular EF (LVEF) <
  50 % followed at our ambulatory from January 2000 to January 2010 were included in the study. 36 patients (20 %) had a LVEF between 41 % and 49 % (HFmrEF), whereas the remaining 179 (80 %) patients had a LVEF ≤40 % (HFrEF). No difference was observed between both groups regarding clinical characteristics. Beta-Blocker (BB) therapy was independently and negatively associated with all-cause mortality in patients with ChCM and HFmrEF by Cox regression analysis (hazard ratio = 0.15
  95 % Confidence Interval 0.05 to 0.42
  p <
  0.001). Survival analysis by Kaplan-Meir method in patients with ChCM with HFmrEF on BB therapy was 49 % in a 60-month follow up. Overall, survival was higher in patients with HFmrEF than in those with HFrEF. Thus, HFmrEF affects 20 % of patients with ChCM, who have similar clinical characteristics and a poorer outcome than patients with ChCM with HFrEF. However, outcome is dismal in patients with ChCM with HFmrEF.